Form 4: Regeneron CFO Christopher Fenimore Sells Shares on August 28, 2024

Regeneron's CFO, Christopher R. Fenimore, executed multiple sales of company stock on August 28, 2024, at prices ranging from approximately $1,204.00 to $1,206.86.

Summary

• On August 28, 2024, Christopher R. Fenimore, the SVP Finance & CFO of Regeneron Pharmaceuticals, Inc., sold shares of the company's common stock.
• The sales were executed at various prices, with volume-weighted average prices ranging from $1,204.71 to $1,206.70.
• Fenimore sold shares directly and indirectly through a 2021 GRAT, a 2022 GRAT, a trust for his daughter, and a trust for his son.
• After the transactions, Fenimore directly owns 15,305 shares of common stock.
• He also indirectly owns shares through a 401(k) plan (1,515 shares), a trust for his spouse (1,897 shares), and various GRATs and trusts for his children.
• The reporting person will provide full information regarding the number of shares sold at each separate price upon request by the Commission staff, the Company, or a security holder of the Company.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock sales by an executive. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company executives. It's common for executives to periodically sell shares for personal financial management.

Stakeholder Impact

• The stock sale by a high-ranking executive could be perceived negatively by some shareholders, although it is a common practice.

Key Dates